Myeloperoxidase gene variation and coronary flow reserve in young healthy men.

[1]  P. Stenvinkel,et al.  A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. , 2003, Kidney international. Supplement.

[2]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[3]  C. Stegeman,et al.  -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. , 2002, Clinical immunology.

[4]  S. Hazen,et al.  Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. , 2002, Blood.

[5]  E J Topol,et al.  Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.

[6]  M. Mulvany,et al.  Influence of Nitric Oxide Synthase and Adrenergic Inhibition on Adenosine-Induced Myocardial Hyperemia , 2001, Circulation.

[7]  J. Eiserich,et al.  Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. , 2001, American journal of physiology. Heart and circulatory physiology.

[8]  T. Lehtimäki,et al.  Effect of Lipid-Lowering Therapy with Pravastatin on Myocardial Blood Flow in Young Mildly Hypercholesterolemic Adults , 2001, Journal of cardiovascular pharmacology.

[9]  G. Siest,et al.  Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms , 2001, European Journal of Human Genetics.

[10]  G. Rouleau,et al.  A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. , 2001, American heart journal.

[11]  S. Barnes,et al.  l-Arginine Chlorination Products Inhibit Endothelial Nitric Oxide Production* , 2001, The Journal of Biological Chemistry.

[12]  A. Unbehaun,et al.  Hypochlorite-modified Low Density Lipoprotein Inhibits Nitric Oxide Synthesis in Endothelial Cells via an Intracellular Dislocalization of Endothelial Nitric-oxide Synthase* , 2001, The Journal of Biological Chemistry.

[13]  J. Crowley,et al.  Increased atherosclerosis in myeloperoxidase-deficient mice. , 2001, The Journal of clinical investigation.

[14]  D. Kutter,et al.  Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit ? , 2000, Acta Haematologica.

[15]  C. Meisel,et al.  Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. , 2000, Cancer research.

[16]  S. Hazen,et al.  Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. , 1999, Circulation research.

[17]  D. Granger.  Ischemia‐Reperfusion: Mechanisms of Microvascular Dysfunction and the Influence of Risk Factors for Cardiovascular Disease , 1999, Microcirculation.

[18]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[19]  J. Viikari,et al.  Coronary flow reserve in young men with familial combined hyperlipidemia. , 1999, Circulation.

[20]  E. Masliah,et al.  Myeloperoxidase Polymorphism Is Associated with Gender Specific Risk for Alzheimer's Disease , 1999, Experimental Neurology.

[21]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[22]  T. Lehtimäki,et al.  Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Heinecke.  Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. , 1998, Atherosclerosis.

[24]  J. Viikari,et al.  Early impairment of coronary flow reserve in young men with borderline hypertension. , 1998, Journal of the American College of Cardiology.

[25]  T. Lehtimäki,et al.  Coronary Flow Reserve Is Reduced in Young Men With IDDM , 1998, Diabetes.

[26]  Jens Pietzsch,et al.  Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. , 1998, Atherosclerosis.

[27]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[28]  J. Deanfield,et al.  Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. , 1997, Circulation.

[29]  S J London,et al.  Myeloperoxidase genetic polymorphism and lung cancer risk. , 1997, Cancer research.

[30]  D. Douer,et al.  An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. , 1997, Blood.

[31]  B. Becher,et al.  Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis , 1997, Journal of Neuroimmunology.

[32]  T. Lehtimäki,et al.  In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. , 1997, Journal of the American College of Cardiology.

[33]  J. Viikari,et al.  Influence of cardiovascular risk status on coronary flow reserve in healthy young men. , 1997, The American journal of cardiology.

[34]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[35]  F. Hsu,et al.  Mass Spectrometric Quantification of Markers for Protein Oxidation by Tyrosyl Radical, Copper, and Hydroxyl Radical in Low Density Lipoprotein Isolated from Human Atherosclerotic Plaques* , 1997, The Journal of Biological Chemistry.

[36]  J. Heinecke.  Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine , 1997, BioFactors.

[37]  J. Viikari,et al.  Coronary flow reserve is impaired in young men with familial hypercholesterolemia. , 1996, Journal of the American College of Cardiology.

[38]  Gordon Vansant,et al.  An Alu Element in the Myeloperoxidase Promoter Contains a Composite SP1-Thyroid Hormone-Retinoic Acid Response Element* , 1996, The Journal of Biological Chemistry.

[39]  R. McIntyre,et al.  NO prevents neutrophil-mediated pulmonary vasomotor dysfunction in acute lung injury. , 1996, The Journal of surgical research.

[40]  R. Stocker,et al.  Presence of hypochlorite-modified proteins in human atherosclerotic lesions. , 1996, The Journal of clinical investigation.

[41]  P. Deininger,et al.  Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers (*) , 1995, The Journal of Biological Chemistry.

[42]  M. Muggeo,et al.  Non-invasive detection of early endothelial dysfunction in hypercholesterolaemic subjects. , 1995, Atherosclerosis.

[43]  O Muzik,et al.  Early Detection of Abnormal Coronary Flow Reserve in Asymptomatic Men at High Risk for Coronary Artery Disease Using Positron Emission Tomography , 1994, Circulation.

[44]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[45]  R. Stocker,et al.  Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. , 1993, The Biochemical journal.

[46]  H. Esterbauer,et al.  The role of lipid peroxidation and antioxidants in oxidative modification of LDL. , 1992, Free radical biology & medicine.

[47]  B. F. Becker,et al.  Different endothelial mechanisms involved in coronary responses to known vasodilators. , 1992, The American journal of physiology.

[48]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[49]  S. Klebanoff.  Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.

[50]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.